130 related articles for article (PubMed ID: 30480028)
1. A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.
Takeshita E; Komaki H; Shimizu-Motohashi Y; Ishiyama A; Sasaki M; Takeda S
Ann Clin Transl Neurol; 2018 Nov; 5(11):1338-1349. PubMed ID: 30480028
[TBL] [Abstract][Full Text] [Related]
2. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.
Komaki H; Maegaki Y; Matsumura T; Shiraishi K; Awano H; Nakamura A; Kinoshita S; Ogata K; Ishigaki K; Saitoh S; Funato M; Kuru S; Nakayama T; Iwata Y; Yajima H; Takeda S
Ann Clin Transl Neurol; 2020 Feb; 7(2):181-190. PubMed ID: 31957953
[TBL] [Abstract][Full Text] [Related]
3. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers.
Takeshita E; Komaki H; Tachimori H; Miyoshi K; Yamamiya I; Shimizu-Motohashi Y; Ishiyama A; Saito T; Nakagawa E; Sugai K; Sasaki M
Brain Dev; 2018 Nov; 40(10):918-925. PubMed ID: 30006121
[TBL] [Abstract][Full Text] [Related]
4. A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old.
Nakagawa T; Takeuchi A; Kakiuchi R; Lee T; Yagi M; Awano H; Iijima K; Takeshima Y; Urade Y; Matsuo M
Clin Chim Acta; 2013 Aug; 423():10-4. PubMed ID: 23603101
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Prostaglandin D Synthase Inhibitor PK007 Decreases Muscle Necrosis in DMD
Yarlagadda S; Kulis C; Noakes PG; Smythe ML
Life (Basel); 2021 Sep; 11(9):. PubMed ID: 34575143
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
7. Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis.
Aoyagi H; Kajiwara D; Tsunekuni K; Tanaka K; Miyoshi K; Hirasawa N
Eur J Pharmacol; 2020 May; 875():173030. PubMed ID: 32084417
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
Saeki T; Noguchi S; Aogi K; Inaji H; Tabei T; Ikeda T
Ann Oncol; 2009 May; 20(5):868-73. PubMed ID: 19150935
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prostaglandin D synthase suppresses muscular necrosis.
Mohri I; Aritake K; Taniguchi H; Sato Y; Kamauchi S; Nagata N; Maruyama T; Taniike M; Urade Y
Am J Pathol; 2009 May; 174(5):1735-44. PubMed ID: 19359520
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.
Sidharta PN; Diamant Z; Dingemanse J
Fundam Clin Pharmacol; 2014 Dec; 28(6):690-9. PubMed ID: 24734908
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.
Saito K; Nagashima H; Noguchi K; Yoshisue K; Yokogawa T; Matsushima E; Tahara T; Takagi S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):577-83. PubMed ID: 24452393
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.
Kumagai Y; Fujita T; Ozaki M; Yokota S; Maeda M; Shida M; Otani Y; Yamaya H; Tsuruta H
Basic Clin Pharmacol Toxicol; 2009 May; 104(5):352-9. PubMed ID: 19175362
[TBL] [Abstract][Full Text] [Related]
18. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
Donovan JM; Zimmer M; Offman E; Grant T; Jirousek M
J Clin Pharmacol; 2017 May; 57(5):627-639. PubMed ID: 28074489
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
Dieterle W; Mann J; Kutz K
Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
